A roadmap to achieve pharmacological precision medicine in diabetes

Abstract

Current pharmacological treatment of diabetes is largely algorithmic. Other than for cardiovascular disease or renal disease, where sodium–glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 receptor agonists are indicated, the choice of treatment is based upon overall risks of harm or side effect and cost, and not on probable benefit. Here we argue that a more precise approach to treatment choice is necessary to maximise benefit and minimise harm from existing diabetes therapies. We propose a roadmap to achieve precision medicine as standard of care, to discuss current progress in relation to monogenic diabetes and type 2 diabetes, and to determine what additional work is required. The first step is to identify robust and reliable genetic predictors of response, recognising that genotype is static over time and provides the skeleton upon which modifiers such as clinical phenotype and metabolic biomarkers can be overlaid. The second step is to identify these metabolic biomarkers (e.g. beta cell function, insulin sensitivity, BMI, liver fat, metabolite profile), which capture the metabolic state at the point of prescribing and may have a large impact on drug response. Third, we need to show that predictions that utilise these genetic and metabolic biomarkers improve therapeutic outcomes for patients, and fourth, that this is cost-effective. Finally, these biomarkers and prediction models need to be embedded in clinical care systems to enable effective and equitable clinical implementation. Whilst this roadmap is largely complete for monogenic diabetes, we still have considerable work to do to implement this for type 2 diabetes. Increasing collaborations, including with industry, and access to clinical trial data should enable progress to implementation of precision treatment in type 2 diabetes in the near future. Graphical abstract

Precision medicine in type 1 diabetes

“…Defining the aetiopathogenesis of type 1 diabetes as a complex autoimmune disease, as summarised by the Eisenbarth model nearly 40 years ago, has opened up the possibility of better prediction, diagnosis and, potentially in the future, prevention of type 1 diabetes. Recently, Florez and Pearson proposed a roadmap to achieve pharmacological precision medicine in monogenic and type 2 diabetes [143]. Inspired by this construct, Fig.…”

Chemical Compounds and Ambient Factors Affecting Pancreatic Alpha-Cells Mass and Function: What Evidence?

“…However, we believe that the potential relevance is remarkable, at least considered in perspective, for the near future. Indeed, there has recently been a vigorous move towards precision medicine in diabetes, including precision diagnostics [ 116 , 117 , 118 , 119 , 120 , 121 , 122 ]. Thus, we expect that soon it may become part of the clinical routine for assessing the specific metabolic defects of a patient with diabetes, or even simple prediabetes or dysglycemia.…”

Pharmakogenetik neuer Glukosespiegelsenker: eine Chance für die Präzisionsmedizin?

“…Therapieschemata und Leitlinien berücksichtigen diese bisher kaum und sind meist nicht auf ursächliche Mechanismenausgerichtet [54]. DieseDiskrepanzim Therapiemanagement trägt womöglich zu einem unterschiedlichen Ansprechen auf die Medikation sowie zu Problemen beim Erreichen der glykämischen Zielwerte bei [12]. Durch Nutzung der personalisierten Medizin können die Komplexität und Heterogenität des Diabetes besser berücksichtigt werden.…”